Online inquiry

IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ633MR)

This product GTTS-WQ633MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets IL9 gene. The antibody can be applied in Asthma research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000590.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3578
UniProt ID P15248
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL9, 7F3com-2H2(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ633MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ195MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ10145MR IVTScrip™ mRNA-Anti-CGRP, LBR-101(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LBR-101
GTTS-WQ1781MR IVTScrip™ mRNA-Anti-IL2RA, ADCT-301(unconjugated)(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ADCT-301(unconjugated)
GTTS-WQ460MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 3G3
GTTS-WQ5332MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ9840MR IVTScrip™ mRNA-Anti-ICOS, JTX-2011(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA JTX-2011
GTTS-WQ15111MR IVTScrip™ mRNA-Anti-ERBB2, SYD985(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SYD985
GTTS-WQ1596MR IVTScrip™ mRNA-Anti-GDF11, ACE-536(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACE-536
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW